Indexado em
- Abra o Portão J
- Genamics JournalSeek
- JournalTOCs
- Diretório de Periódicos de Ulrich
- RefSeek
- Universidade de Hamdard
- EBSCO AZ
- OCLC- WorldCat
- Invocação Proquest
- publons
- Fundação de Genebra para Educação e Pesquisa Médica
- Euro Pub
- Google Scholar
Links Úteis
Compartilhe esta página
Folheto de jornal
Periódicos de Acesso Aberto
- Agro e Aquicultura
- Alimentos e Nutrição
- Bioinformática e Biologia de Sistemas
- Bioquímica
- Ciência de materiais
- Ciencias ambientais
- Ciências Clínicas
- Ciências Farmacêuticas
- Ciências gerais
- Ciências Médicas
- Cuidados de enfermagem e saúde
- Engenharia
- Genética e Biologia Molecular
- Gestão de negócios
- Imunologia e Microbiologia
- Neurociência e Psicologia
- Química
Abstrato
25% Albumin Infusion Maintains Antithrombin III (AT) Activity after AT Agent Administration in Critically Ill Patients with Disseminated Intravascular Coagulation (DIC)
Mayuki Aibiki, Noriyasu Fukuoka, Shiro Bando, Hironori Matsumoto, Muneaki Ohshita, Souichi Maekawam and Jun Takebe
Objective: To report for the first time critically ill patients with disseminated intravascular coagulation (DIC) in whom the infusion of 25% albumin solution produces remarkable elevations in plasma antithrombin III (AT) activities after administration of AT agents.
Design: A prospective observational study. Interventions: 1) Plasma AT activities were serially measured in DIC patients after AT administration, enable us to analyze their pharmacokinetics; 2) Comparisons of AT activities between two groups of receiving AT agent with or without the infusion of 25% albumin solution; 3) in vitro examinations were conducted to define whether albumin application itself would influence directly an AT measurement system using samples already determined the levels of AT activities.
Methods and main results: Twenty consecutive critical patients with DIC were divided into two groups: groups receiving AT agents of 1500 units with (N=11) and without (N=9) the application of 25% albumin solutions. Patients treated with albumin solutions after AT agents showed remarkable elevations in AT peak and trough activities, whereas patients receiving the same dose of the AT agents without albumin co-administration did not maintain its trough activity. Pharmacokinetic analyses revealed that patients had shortened the distribution half-life time of AT, suggesting enhanced vascular permeability. The levels of AT activities in patients treated with both albumin and AT agents (N=11) were significantly higher than those without albumin administration (N=9, p=0.01). Furthermore, in vitro albumin applications to the AT measurement system did not effect on its values in the samples.
Conclusion: This is the first report indicating that 25% albumin administration could elevate and sustain AT activities, even when a limited AT dose was administered to DIC patients with increased vascular permeability. This may be due to a certain binding effect of albumin, which needs to be defined in the future.